The $200,000 woman: How donors' tissue is turned into boob jobs and butt lifts

The $200,000 woman: How donors' tissue is turned into boob jobs and butt lifts

Getty Images; Alyssa Powell/BI Getty Images; Alyssa Powell/BI Sometime before May, somewhere near St. Louis, Missouri, a 45-year-old woman died.By the end of July, nearly 8 pounds of fat had been cut off her body, frozen, shipped to Texas, run through a meat grinder, processed with chemicals to remove her genetic material, centrifuged several times, and packed into more than 70 syringe-like tubes.The containers were blasted with gamma radiation, packed into dozens of yellow boxes, and shipped to plastic surgeons' offices. Her fat had been turned into alloClae, a hot, new injectable product being used to lift butts, augment breasts, and fill in hip dips for deep-pocketed patients across the country. It was enough to supply procedures that would cost around $200,000, a Business Insider investigation found.Human tissue can generate enormous revenue. Documents reviewed by Business Insider offer the first detailed look at the economics of alloClae, and reveal how its for-profit producer, Tiger Biosciences, turns a few pounds of donated tissue into a product used for procedures that can cost tens of thousands of dollars. The reporting sheds new light on the commercial value of a human body after death, and includes never-before-reported details on the money being made from processing human tissue into cosmetic products. Under US law, donors and their families can't be paid.The recovery and processing of tissue is a multibillion-dollar industry in the US. Tissue recovered from a single donor — most commonly skin, bone, and corneas, but sometimes also tendons and ligaments, veins, or heart valves — can be worth tens or hundreds of thousands of dollars to companies like Tiger, depending on the cost to recover and process them.Donated tissue is used in skin grafts for burn victims, reconstructive surgery for breast cancer survivors, and replacement valves for heart patients. For decades, it has also been used in cosmetic surgery, including cartilage for nose jobs and skin for breast augmentations.Now, a new family of injectable cosmetic products made from human tissue can be administered in under an hour. AlloClae is not alone. At least two other US companies make injectable cosmetic products from cadaver fat. And in South Korea, at least 10 companies are making or planning beauty injections made from ground-up skin, largely from US donors.Tiger Biosciences co-CEO Oliver Burckhardt told staff earlier this year that the company was betting big on alloClae and other products made from cadaver fat."I mean, in 30 years I've been doing this right now, I never had a more amazing technology," he said.Tiger's chief legal officer, Larry Wood Jr., told Business Insider its reporting was "neither accurate nor fair." He declined to specify what was inaccurate. He also said Business Insider had obtained confidential information.Wounded TigerSince hitting the market in 2024, alloClae has been a hot commodity at the offices of exclusive plastic surgeons, whose patients are willing to spend six figures on some alloClae procedures.It is partly about convenience. No longer do patients wanting a boob job or a butt lift have to undergo general anesthesia. The rise in GLP-1 weight-loss drugs has fueled demand for alloClae. Patients come in not only for Ozempic face — but also for deflated breasts, hips, and butts.Some doctors have had to queue up on wait lists to obtain alloClae. The product has become a minor plot point in two Real Housewives franchises. Plastic surgeons have called it "liquid gold," "pure gold on demand," and "revolutionary."For its manufacturer, Tiger Biosciences, alloClae could be a life preserver.Heading into 2026, Tiger's top revenue stream was from wound-care products made from donated birth tissue. Then Tiger and several other businesses were sent reeling by the federal government's decision to slash Medicare spending on skin substitutes. Tiger conducted layoffs and projected in April that its sales would fall 75% this year compared to last year, according to an internal company presentation.In the April staff meeting, Burckhardt outlined a new strategy, according to a recording of the meeting reviewed by Business Insider.To get back to profitability, he said, the company would focus on alloClae and other products derived from cadaver fat, also known as adipose tissue. A slide in Burckhardt's presentation described alloClae as "high-growth," "high-margin" and "high-demand." Burckhardt described it as a cornerstone of the company's revenue moving forward.First, the company needs more tissue."Without tissue, we don't have a sales strategy," Burckhardt said in the April staff meeting. Tiger Biosciences co-CEO Oliver Burckhardt presented at a staff meeting in April. Obtained by Business Insider Tiger was working on securing more supply, Burckhardt said. He outlined a strategy to win over additional suppliers — the largely nonprofit organ procurement organizations and tissue banks that recover tissue from donors."We need to drive awareness for natural beauty products so that the overall tissue recovery community understands what we do with the tissue that we are collecting and what our values are," he said. "We have to convince the marketplace that we are good stewards of the tissue and that we're not doing something we're not supposed to be doing with the tissue."At an October tissue industry conference in San Francisco, a booth for Tiger subsidiary Biocare Donor Network displayed a diagram of adipose tissue. A banner in the booth said the company works with procurement agencies "to ensure Donor Heroes and their selfless gifts make a meaningful impact.""We ensure that each gift is protected, respected, and impactful," it said.From donors to dollarsTissue donation often begins at a motor vehicles department, where about half of organ and tissue donors sign up by checking a box. If someone doesn't register during their lifetime, their family can authorize donation when they die.Organ distribution is coordinated in conjunction with the federal government. Tissue, on the other hand, is distributed through commercial relationships. A booth for Tiger subsidiary Biocare Donor Network displays a diagram of adipose tissue. Jack Newsham A tissue bank or federally designated organ procurement organization physically recovers the tissue. These organizations have been under increased scrutiny over the past year. The House Committee on Ways and Means has been investigating organ procurement organizations, including allegations of Medicare fraud and the collection of organs and tissues without informed consent by donors or their families.$0: Amount the 45-year-old's family was paid for her donationA Tiger subsidiary pays fees to tissue banks and organ procurement organizations to collect tissue from donors. The fee covers the cost of the tissue recovery as well as a margin that supports other programs offered by the organization.In the first half of this year, Tiger's manufacturing subsidiary, RegenTX, processed fat from close to 700 cadavers from nine suppliers across 12 states, records show.An organ procurement organization called Mid-America Transplant Services recovered fat from the 45-year-old woman's body.It's not clear whether she had agreed to donate her organs and tissue through a DMV or if her family authorized it after her death. A family authorization form used by Mid-America Transplant says tissue may be used for profit and may be used for any lawful purpose; it doesn't specify cosmetic procedures. It does allow authorizers to specify limitations. About half of organ and tissue donors sign up at a DMV. (AP Photo/Patrick Sison, File) Patrick Sison/AP The organization recovers tissue from donors in eastern Missouri, southern Illinois, and parts of Arkansas. The Missouri and Illinois DMVs, like those in many other states, don't mention cosmetic or for-profit uses in written material for donors. Arkansas doesn't have a written form or fact sheet; DMV agents ask people verbally if they wish to be organ donors.Mid-America Transplant said its responsibility is to treat each donor's gift with respect and ensure that it "can provide a meaningful benefit to others.""We cherish the privacy of each donor and are constantly evolving the ways we provide education to the community to improve understanding about organ and tissue donation," said Mid-America Transplant Executive Vice President Lindsey Speir. "Organ and tissue donation provides lifesaving and life-changing healing, and our responsibility is to honor our donor heroes, steward their gift, and care for their families with dignity and respect." By July 3, the fat collected from the 45-year-old woman had been delivered to San Antonio, and was ready to begin the daylong process of being turned into alloClae.The process includes at least five steps, intended to isolate fat from any other tissue in the sample and eliminate any viruses or microbes.Throughout alloClae's production process, large quantities of donor tissue get thrown away, according to internal records and former employees. In the April presentation, Burckhardt said the company was working on improving its fat tissue yields.Tissue must be repeatedly tested to ensure that no diseases could be transmitted to a recipient under safety rules set by the Food and Drug Administration and the Association for Advancing Tissue and Biologics, a trade group. Some tissue is discarded because it isn't fat; some fat is discarded because it doesn't have the right consistency to be processed. Of the total weight of tissue received for processing, less than 20% is packaged, and about a quarter of that packaged fat is discarded, according to internal records.$80,000: Estimated amount that Tiger would be paid for 74 containersThe fat from the St. Louis-area woman passed the test. Her fat was packaged into 74 syringe-like containers and was shipped out to doctors' offices. Tiger's website lists qualified providers in 40 states.There are few other uses for cadaver fat. Some experimental treatments are made from stem cells derived from fat tissue; the FDA has not approved any treatments that use them.While it is not known exactly how much Tiger charged for the alloClae derived from this woman's tissue, records submitted in a legal dispute between Tiger and a New York regulator show that one surgeon paid an average of $86.29 per cubic centimeter of alloClae. In interviews, other plastic surgeons described paying roughly similar amounts. At that price, 74 containers of 12.5 cubic centimeters each would have brought in about $80,000 for Tiger.For treatments involving alloClae, plastic surgeons can charge between $1,500 and $4,500 per container, according to online advertisements and interviews with doctors. Based on that price range, procedures using the 74 tubes containing the 45-year-old woman's fat would cost patients a total of between $111,000 and $333,000.San Francisco-based plastic surgeon David Sieber told Business Insider last year that for a procedure involving four to eight containers of alloClae, patients could pay tens of thousands of dollars."The thing that shocks me a little bit is just how expensive the product is, but still the willingness of patients to pay for it," he said. Exclusive Health Most popular Business Insider tells the stories you want to know about the world of business, technology, and finance Business Insider tells the stories you want to know about the world of business, technology, and finance Business Insider tells the stories you want to know about the world of business, technology, and finance Business Insider tells the stories you want to know about the world of business, technology, and finance Business Insider tells the stories you want to know about the world of business, technology, and finance Business Insider tells the stories you want to know about the world of business, technology, and finance Madeline Berg is a correspondent at Business Insider, where she covers the wealthy, famous, and powerful. Her stories include analyses of some of the most well known billionaires, from Mark Zuckerberg to MrBeast, investigations into celebrity brands, and deep dives into figures like Jeffrey Epstein and Leon Black.Previously, she was at Forbes. Her work included cover stories on Tyler Perry and Shonda Rhimes, investigations into Kylie Jenner's beauty brand, and deep dives into Britney Spears' fortune. Madeline has also written for The New York Times, The New York Observer, and Racked. She regularly appears on panels, on television, and in documentaries discussing the entertainment industry and general business news.Contact her via email at mberg@insider.com or by phone, Signal, or WhatsApp at 914-420-4721. https://www.businessinsider.com/secure-news-tips. Jack is a correspondent on Business Insider's enterprise desk.He focuses on money, power, and big names in business, politics and entertainment. In his decade-plus in journalism, he has written about prediction markets including Kalshi and Polymarket, tech companies like Google, entertainers and musicians like Lil Wayne and Marshmello, and various nonprofits and healthcare companies. He has extensive experience writing about law firms, litigation, and regulation.Contact information is included below. Please only send Jack pitches by email. If you have sensitive information to share, please connect on Signal using the information below. Use a personal phone and a personal data or WiFi connection. He is originally from St. Louis, and graduated from Yale with a bachelor's degree in economics.

Original Source

Read the full article at Businessinsider →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.